These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29913350)

  • 1. NT-proBNP is a potential mediator between reduced ejection fraction and depression in patients with heart failure.
    Zuzarte P; Scola G; Duong A; Kostiw K; Figueira ML; Costa-Vitali A
    J Psychiatr Res; 2018 Sep; 104():8-15. PubMed ID: 29913350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
    Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
    Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality.
    van den Broek KC; Defilippi CR; Christenson RH; Seliger SL; Gottdiener JS; Kop WJ
    Am J Cardiol; 2011 Mar; 107(5):723-9. PubMed ID: 21316507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
    Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
    Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
    JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
    Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.